论文部分内容阅读
[目的]探讨非小细胞肺癌(NSCLC)新辅助化疗客观疗效对18氟脱氧葡萄糖(18FDG)SUVmax(最大标准化摄取值)及VEGF表达的影响。[方法]回顾性分析41例对新辅助化疗的NSCLC患者,其中24例患者化疗结束后行全身18FDG-PET,术后用免疫组化法检测原发灶VEGF表达情况,用独立样本t检验比较新辅助化疗有效组与无效组的平均SUVmax,用χ2检验比较两组的原发灶VEGF表达情况。[结果]新辅助化疗有效12例,无效29例,其中作了全身18FDG-PET的有效组(10例)与无效组(14例)的平均SUVmax分别为5.43±3.44和5.26±4.13,差异无显著性(P>0.05)。有效组患者VEGF表达阳性率为41.7%(5/12),显著低于无效组的75.9%(22/29)(P<0.05)。[结论]NSCLC新辅助化疗有效组与无效组的平均SUVmax无显著性差异;有效组的原发灶VEGF表达阳性率显著性低于无效组。
[Objective] To investigate the objective effect of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) on the expression of 18 F-FDG SUVmax and VEGF. [Methods] A total of 41 NSCLC patients undergoing neoadjuvant chemotherapy were retrospectively analyzed. Twenty-four patients underwent complete 18FDG-PET after chemotherapy. VEGF expression in the primary tumor was detected by immunohistochemistry after operation. Neoadjuvant chemotherapy group and the effective group of the average SUVmax, χ2 test was used to compare VEGF expression of the two groups. [Results] Neoadjuvant chemotherapy was effective in 12 cases and ineffective in 29 cases. The average SUVmax of the effective group (10 cases) and the ineffective group (14 cases) with systemic 18FDG-PET was 5.43 ± 3.44 and 5.26 ± 4.13, respectively, with no difference Significance (P> 0.05). The positive rate of VEGF expression in effective group was 41.7% (5/12), significantly lower than that in ineffective group (75.9%, 22/29) (P <0.05). [Conclusion] The average SUVmax of NSCLC neoadjuvant chemotherapy group is not significantly different from that of ineffective group. The positive expression rate of VEGF in effective group is lower than that in ineffective group.